SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) posted its quarterly earnings results on Thursday. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.26), Briefing.com reports. SpringWorks Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.97) EPS.
SpringWorks Therapeutics Stock Performance
Shares of SWTX stock traded up $2.47 during midday trading on Friday, reaching $36.86. 1,173,134 shares of the company were exchanged, compared to its average volume of 806,107. The company’s 50 day moving average price is $25.72 and its two-hundred day moving average price is $42.74. The company has a market cap of $1.82 billion, a P/E ratio of -8.69 and a beta of 0.82. SpringWorks Therapeutics has a 12 month low of $13.60 and a 12 month high of $88.05.
Wall Street Analysts Forecast Growth
SWTX has been the topic of a number of research reports. HC Wainwright dropped their price target on SpringWorks Therapeutics from $142.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, June 6th. The Goldman Sachs Group lowered their price target on shares of SpringWorks Therapeutics from $92.00 to $76.00 and set a “buy” rating for the company in a research report on Tuesday, May 24th. Finally, Wedbush set a $53.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday, June 20th.
Institutional Inflows and Outflows
SpringWorks Therapeutics Company Profile
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.